...
首页> 外文期刊>Seminars in liver disease >Noncoding RNA in Cholangiocarcinoma
【24h】

Noncoding RNA in Cholangiocarcinoma

机译:胆管癌中的非致rna

获取原文
获取原文并翻译 | 示例
           

摘要

Cholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is a key challenge because of the lack of specific symptoms, and the curability rate is low due to the difficulty in achieving a radical resection and the intrinsic chemoresistance of CCA cells. Noncoding RNAs (ncRNAs) are transcripts that are not translated into proteins but exert their functional role by regulating the transcription and translation of other genes. The discovery of the first ncRNA dates back to 1993 when the microRNA (miRNA) lin-4 was discovered in Caenorhabditis elegans. Only 10 years later, miRNAs were shown to play an oncogenic role in cancer cells and within 20 years miRNA therapeutics were tested in humans. Here, the authors review the latest evidence for a role for ncRNAs in CCA and discuss the promise and challenges associated with the introduction of ncRNAs into clinical practice.
机译:胆管癌(CCA)是具有令人沮丧的肿瘤预后。 由于缺乏特异性症状,早期诊断是一个关键挑战,并且由于难以实现自由基切除和CCA细胞的内在化学抑制,可固化率低。 非沉积的RNA(NCRNA)是未转化为蛋白质的转录物,但通过调节其他基因的转录和翻译来发挥其功能作用。 当MicroRNA(miRNA)在Caenorhabditis的秀丽隐患中发现MicroRNA(miRNA)Lin-4时,对第一个NCRNA的发现返回1993年。 只有10年后,MiRNA被证明在癌细胞中发挥致癌作用,20年内在人体中测试了miRNA治疗剂。 在这里,作者审查了CCA中NCRNA的作用的最新证据,并讨论了与将NCRNA引入临床实践的承诺和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号